Journal of Clinical Oncology
Articles in this Issue
Role of circulating tumor DNA (ctDNA) in locally advanced (LA) and metastatic urothelial cancer (mUC).
685 Background: The role of ctDNA is emerging as an adjunctive prognostic tool for survival in the laUC setting, but its role is evolving in mUC. We aimed...
Efficacy and safety of fexagratinib (Fexa) in combination with tislelizumab (T) in a phase II study of patients (pts) with locally advanced or metastatic urothelial carcinoma (mUC) harboring FGFR alterations (FGFRa).
789 Background: A significant proportion of pts with mUC are intolerant to platinum-based chemotherapy, highlighting the urgent need for alternatives. Fex...
The analysis of active surveillance for Japanese young early-stage prostate cancer patients: From the PRIAS-JAPAN study.
351 Background: The current status of active surveillance (AS) for early-stage young Japanese patients is unknown. We examined it from the data of PRIAS-J...
Impact of PSMA-PET and conventional imaging on contemporary management in patients with biochemical recurrence after radical prostatectomy.
43 Background: Prostate-specific membrane antigen (PSMA) PET imaging is recommended for patients with biochemical recurrence (BCR) after radical prostatec...
Epigenomic profiling of circulating chromatin for early detection and monitoring of neuroendocrine prostate cancer.
253 Background: Neuroendocrine prostate cancer (NEPC) is an aggressive subtype of prostate cancer that can arise after androgen blockade. Early detection...
SUBDUE-3: Sub-urothelial durvalumab-sirconium to investigate local and systemic distribution of durvalumab when injected in the sub-urothelium.
TPS903 Background: Sub-urothelial injection of durvalumab presents a novel therapeutic approach for bladder cancer. SUBDUE...
Adherence to clinical surveillance guidelines in von Hippel-Lindau (vHL) disease: Evaluating the impact of a coordinated care centre implementation in Canada.
460 Background: VHL is a rare hereditary cancer syndrome, predisposing to the development of multiorgan tumour growth, including bilateral and recurrent c...
Who undergoes cytoreductive nephrectomy now? An analysis of perioperative risk characteristics in contemporary patients.
493 Background: Cytoreductive nephrectomy (CN) has traditionally been the first step in managing metastatic renal cell carcinoma (mRCC). However, the role...
Intravesical gemcitabine and docetaxel combined with intravenous tislelizumab as a durable strategy for high-risk non–muscle-invasive bladder cancer.
703 Background: For decades, intravesical Bacillus Calmette-Guérin (BCG) has been the standard treatment for high-risk non-muscle-invasive bladder cancer...
RAD-SG: Adaptive radiation therapy with concurrent sacituzumab govitecan (SG) for bladder preservation in patients (pts) with muscle invasive bladder cancer (MIBC).
TPS896 Background: Concurrent chemoradiotherapy (CRT) is a recommended treatment option for pts with MIBC interested in bladder-preservation and/or not ca...
Individualized neoantigen vaccine with nivolumab plus cabozantinib for translocation renal cell carcinoma: Single patient investigational new drug.
537 Background: Translocation renal cell carcinoma (tRCC) is a rare renal cell carcinoma subtype found in about 1-4% of adult patients with RCC and 40% of...
Impact of adding immunotherapy to chemotherapy for metastatic neuroendocrine bladder cancer in the National Cancer Database.
748 Background: Metastatic neuroendocrine bladder cancer is a rare and aggressive malignancy characterized by poor prognosis and limited effective treatme...
Determining an immunohistochemical profile to predict response to intravesical bacillus Calmette–Guérin (BCG) in patients with high-grade non-muscle invasive bladder cancer.
847 Background: Intravesical Bacillus Calmette–Guérin (BCG) remains the gold standard for the management of high-grade non-muscle invasive bladder cancer...
Evaluating the impact of single vs. combination therapy on survival outcomes in mHSPC patients stratified by BMI.
187 Background: Metastatic hormone sensitive prostate cancer (mHSPC) is a heterogenous disease with a variety of treatment options. De novo mHSPC can be t...
Clinical outcomes of invasive primary urethral cancer: A real world multi-institutional study.
654 Background: Primary urethral cancer (PUC) is a rare and highly aggressive malignancy with a spectrum of various histologies without an established tre...
Phase III randomized trial of stereotactic ablative radiotherapy (SAbR) for oligometastatic advanced renal carcinoma (EA8211-SOAR).
TPS615 Background: The optimal frontline management strategy for oligometastatic renal cell carcinoma (omRCC) is uncertain. Systemic therapy (ST) is the s...
A prospective trial of a structured exercise program to lessen fatigue in patients with advanced prostate cancer (aPC) undergoing androgen deprivation therapy (ADT).
120 Background: Cancer-related fatigue, one of the most significant issues affecting quality of life (QOL), is reported by up to 75% of men with advanced...
World-wide oligometastatic prostate cancer (omPC) meta-analysis leveraging individual patient data (IPD) from randomized trials (WOLVERINE): An analysis from the X-MET collaboration.
15 Background: Metastasis-directed therapy (MDT) for omPC has demonstrated progression-free survival (PFS) benefit in multiple phase 2 randomized clinical...
Characterization, treatment and survival outcomes of penile cancer: Over a decade in a tertiary Mexican center.
5 Background: Penile cancer, as a rare disease worldwide, represents 4.1% of urological cancers in Mexico. Despite the need for multimodal treatments, del...
Prostate Cancer Supportive Care (PCSC) program: An alternative to consolidated framework for implementation research (CFIR) model.
346 Background: The CFIR model is one approach to implementing supportive care services. It requires extensive resources, staff training, and reliance on...
Implementation and preliminary validity of the Functional Assessment of Cancer Therapy – Radionuclide Therapy (FACT-RNT) in patients receiving radionuclide therapy for prostate cancer.
118 Background: The Functional Assessment of Cancer Therapy-Radionuclide Therapy (FACT-RNT) is used in trials and clinical practice to monitor patient-rep...
Comparative survival outcomes of non-clear cell and clear cell renal cell carcinomas with indications for adjuvant pembrolizumab.
515 Background: While immunotherapy has become first-line treatment for metastatic renal cell carcinoma in both clear cell (ccRCC) and non-clear cell (ncc...
Impact of BRCA status in patients with castrate-resistant prostate cancer undergoing abiraterone +/- stereotactic body radiotherapy: ARTO trial.
397 Background: ARTO (NCT03449719) was a multicenter randomized phase II trial exploring the benefit of concomitant Abiraterone acetate and stereotactic b...
Real-world epidemiology and clinical outcomes of bladder cancer patients in Spain: BLARWE multicenter study.
702 Background: Bladder cancer (BC) is one of the most prevalent oncologic diseases in the world, and its incidence in Spain is among the highest in Europ...
The prognostic significance of circulating tumor DNA in prostate cancer: A systematic review and meta-analysis.
214 Background: Circulating tumor DNA (ctDNA) has attracted increasing interest as a biomarker in multiple cancers. This study aimed to perform a systemat...